John Kitchens, MD

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability, with treatment selection ultimately guided by patient characteristics and future labeling.

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising questions about long-term disease chronicity and vascular remodeling under sustained VEGF suppression.

Panelists discuss how faricimab and aflibercept 8 mg compare in drying and durability and how clinicians manage IOP considerations tied to injection frequency, volume, and syringe variability.

Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize durability and outcomes, particularly in undertreated patients.

Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden while maintaining familiarity for patients across AMD and DME.

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic impact.

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.